Compass Therapeutics (CMPX) financial statements
Compass Therapeutics reported revenue of $0 in fiscal 2025.
Net income was -$66M.
Free cash flow was -$49M.
The diluted share count rose 3054% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Compass Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $850,000 | $0 |
| Research and development | — | $22M | — | $15M | $20M | $30M | $38M | $42M | $56M |
| Selling, general and admin | $32,759 | $12M | $32,105 | $13M | $11M | $12M | $12M | $15M | $17M |
| Operating income | -$32,759 | -$34M | -$32,105 | -$28M | -$82M | -$42M | -$50M | -$57M | -$73M |
| Interest expense | $3,278 | $1M | $5,378 | $908,000 | $370,000 | $0 | — | — | — |
| Pre-tax income | — | -$35M | — | -$29M | -$82M | -$39M | -$42M | — | — |
| Income tax | — | $91,000 | — | $32,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$36,037 | -$35M | -$37,483 | -$30M | -$82M | -$39M | -$42M | -$49M | -$66M |
| EPS (diluted) | -$0.01 | -$5.19 | -$0.01 | -$0.96 | -$1.31 | -$0.37 | -$0.33 | -$0.36 | -$0.42 |
| Diluted shares | 5M | 7M | 5M | 31M | 63M | 105M | 127M | 137M | 158M |
| Operating margin | — | — | — | — | — | — | — | -6661.8% | — |
| Net margin | — | — | — | — | — | — | — | -5808.8% | — |
Balance sheet
Fiscal years, from Compass Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $4,866 | $25M | $3,745 | $47M | $145M | $187M | $152M | $127M | $209M |
| Total current assets | $4,866 | $26M | $3,745 | $50M | $147M | $195M | $154M | $133M | $210M |
| Property, plant and equipment | — | $4M | — | $1M | $2M | $2M | $898,000 | $353,000 | $102,000 |
| Total assets | $4,866 | $30M | $3,745 | $52M | $154M | $200M | $157M | $140M | $220M |
| Total current liabilities | $75,455 | $10M | $111,817 | $10M | $11M | $16M | $8M | $9M | $14M |
| Long-term debt | — | $9M | — | $2M | $0 | — | — | — | — |
| Total liabilities | $75,455 | $19M | $111,817 | $12M | $14M | $18M | $8M | $15M | $23M |
| Shareholders' equity | -$95M | $11M | -$125M | $40M | $140M | $182M | $149M | $125M | $197M |
| Net debt | -$4,866 | -$10M | -$3,745 | -$38M | -$145M | -$35M | -$24M | -$43M | -$31M |
Cash flow
Fiscal years, from Compass Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32,759 | -$32M | -$32,106 | -$27M | -$20M | -$34M | -$41M | -$45M | -$49M |
| Capital spending | — | $466,000 | — | $106,000 | $2M | $212,000 | $30,000 | $44,000 | $25,000 |
| Free cash flow | — | -$32M | — | -$27M | -$21M | -$34M | -$41M | -$45M | -$49M |
| Stock-based compensation | — | $915,000 | — | $4M | $4M | $5M | $6M | $9M | $8M |
| Net borrowing | — | — | — | -$6M | -$9M | $0 | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — | -5282.2% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CMPX.
Open CMPX in InvestinglyQuestions
What was Compass Therapeutics's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Compass Therapeutics generate?
-$49M in fiscal 2025 (operating cash flow minus capital spending).
From Compass Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.